

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

LN-319

RRID:CVCL_3958

Type: Cell Line

Proper Citation

RRID:CVCL_3958

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3958

Proper Citation: RRID:CVCL_3958

Description: Cell line LN-319 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Astrocytoma

Defining Citation: [PMID:7693337](#), [PMID:7732013](#), [PMID:9842975](#), [PMID:10416987](#), [PMID:14614447](#), [PMID:14655754](#), [PMID:17595512](#), [PMID:21406405](#), [PMID:22570425](#), [PMID:25984343](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Shown to be a LN-992 derivative (PubMed=22570425)..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LN-319

Synonyms: LN 319, LN319

Cross References: BTO:BTO_0002215, AddexBio:C0005001/54, BioSample:SAMN03151824, BioSample:SAMN10988411, cancercellines:CVCL_3958, Cell_Model_Passport:SIDM01626, Cosmic:849864, Cosmic:2367493, Cosmic:2516027, DepMap:ACH-000128, GEO:GSM397667, GEO:GSM397668, IARC_TP53:2572, PharmacDB:LN319_843_2019, Wikidata:Q54902776

ID: CVCL_3958

Hierarchy: cvcl_6845

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260815T234508+0000

Ratings and Alerts

No rating or validation information has been found for LN-319.

Warning: Problematic cell line: Contaminated. Shown to be a LN-992 derivative (PubMed=22570425).

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00450.

Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Shown to be a LN-992 derivative (PubMed=22570425)..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sallbach J, et al. (2024) The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 181, 117634.

Khadka S, et al. (2023) Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism. *bioRxiv : the preprint server for biology*.

Zhang M, et al. (2020) Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. *Frontiers in genetics*, 11, 363.

von Achenbach C, et al. (2020) Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. *Journal of neurochemistry*, 153(4), 510.

Zhang M, et al. (2020) Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma. *Frontiers in genetics*, 11, 441.

von Achenbach C, et al. (2018) Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. *Journal of neurochemistry*, 147(1), 99.